Literature DB >> 10834826

Bacteraemia caused by non-glucose-fermenting gram-negative bacilli and Aeromonas species in patients with haematological malignancies and solid tumours.

R Martino1, L Gómez, R Pericas, R Salazar, C Solá, J Sierra, J Garau.   

Abstract

The clinical characteristics and outcome of bacteraemia caused by non-glucose-fermenting gram-negative bacilli and Aeromonas spp. were examined in 115 adults with haematological malignancies or solid tumours. The most aggressive pathogens were Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Aeromonas spp., Acinetobacter spp. and Burkholderia cepacia, all of which caused either septic syndrome or pneumonia in more than 40% of cases. Pseudomonas aeruginosa was involved less often in catheter-related bacteraemia than other species. Polymicrobial bacteraemia (n=28) was more often catheter-related than monomicrobial bacteraemia and more often required catheter removal for definitive cure. The most important predictors of catheter-related bacteraemia and its outcome were polymicrobial infection, the presence of pneumonia or septic syndrome and the species involved.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10834826     DOI: 10.1007/s100960050485

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  Infections and bacterial colonization during cytotoxic therapy in patients with acute leukemia.

Authors:  O Perola; T Nousiainen; J Pentikäinen; A Laatikainen; M L Katila
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-11       Impact factor: 3.267

2.  Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004.

Authors:  G Aisenberg; K V Rolston; B F Dickey; D P Kontoyiannis; I I Raad; A Safdar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 3.267

3.  Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients.

Authors:  D Averbuch; E Horwitz; J Strahilevitz; P Stepensky; N Goldschmidt; M E Gatt; M Y Shapira; I B Resnick; D Engelhard
Journal:  Infection       Date:  2013-05-08       Impact factor: 3.553

4.  Changing trends in etiology of bacteremia in patients with cancer.

Authors:  A Safdar; G H Rodriguez; M Balakrishnan; J J Tarrand; K V I Rolston
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

Review 5.  Bloodstream infections in patients with solid tumors.

Authors:  Carlota Gudiol; José María Aguado; Jordi Carratalà
Journal:  Virulence       Date:  2016-01-19       Impact factor: 5.882

6.  Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections.

Authors:  E Velasco; R Byington; C A S Martins; M Schirmer; L M C Dias; V M S C Gonçalves
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

7.  Revisited distribution of nonfermenting Gram-negative bacilli clinical isolates.

Authors:  H Jacquier; E Carbonnelle; S Corvec; M Illiaquer; A Le Monnier; E Bille; J R Zahar; J L Beretti; F Jauréguy; V Fihman; J Tankovic; V Cattoir
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-21       Impact factor: 3.267

8.  A case of native valve endocarditis caused by Burkholderia cepacia without predisposing factors.

Authors:  Hyun Kyun Ki; Sung Hea Kim; Seong Woo Han; Hae Suk Cheong
Journal:  BMC Infect Dis       Date:  2011-05-08       Impact factor: 3.090

9.  Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in adult surgical cancer patients.

Authors:  E Velasco; M Soares; R Byington; C A S Martins; M Schirmer; L M C Dias; V M S Gonçalves
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-28       Impact factor: 3.267

10.  Implantable venous port-related infections in cancer patients.

Authors:  Wen-Tsung Huang; Tsai-Yun Chen; Wu-Chou Su; Chia-Jui Yen; Chao-Jung Tsao
Journal:  Support Care Cancer       Date:  2004-01-16       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.